Comparing Neuphoria Therapeutics (NEUP) and Its Competitors

Neuphoria Therapeutics (NASDAQ:NEUP) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Neuphoria Therapeutics to related businesses based on the strength of its valuation, dividends, earnings, risk, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Neuphoria Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	-$370,000.00	-0.93
Neuphoria Therapeutics Competitors	$947.76 million	-$45.20 million	11.71

Neuphoria Therapeutics’ competitors have higher revenue, but lower earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Neuphoria Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics’ competitors have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Neuphoria Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	0	2	0	2.33
Neuphoria Therapeutics Competitors	5929	12239	37704	1174	2.60

Neuphoria Therapeutics currently has a consensus price target of $28.00, indicating a potential upside of 519.47%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 49.90%. Given Neuphoria Therapeutics’ higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than its competitors.

Profitability

This table compares Neuphoria Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-53.17%	-36.15%
Neuphoria Therapeutics Competitors	-1,425.99%	-589.65%	-28.81%

Summary

Neuphoria Therapeutics competitors beat Neuphoria Therapeutics on 8 of the 13 factors compared.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.